Oak Hill Bio

Oak Hill Bio is a clinical-stage company focused on developing life-changing therapies for newborns and rare diseases, targeting preterm infants and patients with rare autoimmune disorders. Oak Hill Bio was established to advance a portfolio of promising clinical and preclinical therapeutic candidates, bringing innovation to challenging drug development areas that have seen minimal progress over the past two decades. Our team combines expertise in rare diseases and neonatology with the experience and acumen necessary to navigate regulatory approvals and ultimately deliver new therapies to patients in need.